J&J declares a historic success as Invokana comes through in PhIII chronic kidney disease trial
J&J has scored positive data from its Phase III chronic kidney disease study of the SGLT2 diabetes drug Invokana, possibly opening the door to a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
